Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) shareholders have seen the share price descend 16% over the month. But that...